Filing Flows

Filing Flows › Sensus Healthcare (SRTS) › Q2 2025

Sensus Healthcare (SRTS) Q2 2025 earnings results (second quarter 2025)

10-Q filed Aug 12, 2025

Sensus Healthcare (SRTS) reported revenue of $7.3M for the second quarter 2025 (Q2 2025), -21% from a year earlier and -12% from the quarter before. Operating margin was -26.6%, net loss $1.0M (14.2% of revenue).

Revenue$7.3M
Year over year-21%
Quarter over quarter-12%
Operating margin-26.6%
Net earnings−$1.0M

Sensus Healthcare, Q2 2025: revenue $7.3M (-21% year over year), operating margin -26.6%, net loss $1.0M, operating cash flow $3.1M. The chart follows the revenue to costs, profit and cash.

Q2 2025AmountQ/QY/Y
Revenue$7.3M-12%-21%
Operating profit−$1.9M——
Net earnings−$1.0M——
Operating cash flow$3.1M—-26%
Free cash flow$3.1M—-27%

What changed

Revenue was $7.3M in Q2 2025, down 21% year over year and down 12% from the previous quarter. Product was the largest line at 74% of revenue. Product lost $2.7M year over year (down 33%), 140% of the total change.

Gross margin was 39.7%, down 19.0 points from a year earlier. Operating costs exceeded revenue by $1.9M, an operating margin of -26.6%. Operating expenses grew 41% against a revenue fall of 21%. The fastest-growing cost line was Research & development (+70%). The quarter ended with a net loss of $1.0M, narrower than the previous quarter's $2.6M loss.

Operating cash flow was $3.1M (down 26% year over year). Non-cash charges added back $99K of depreciation and $67K of share-based compensation. Working capital and other items added $4.0M. Capital expenditures of $27K left free cash flow of $3.1M.

Questions

What was Sensus Healthcare's revenue in the second quarter 2025?

Sensus Healthcare (SRTS) reported revenue of $7.3M for the second quarter 2025 (Q2 2025), -21% from a year earlier and -12% from the quarter before.

Was Sensus Healthcare profitable in the second quarter 2025?

Operating loss was $1.9M (-26.6% of revenue) and net loss $1.0M.

Open the interactive Sankey →

Source: Sensus Healthcare 10-Q on SEC EDGAR.